P. Roy Vagelos's most recent trade in Regeneron Pharmaceuticals, Inc. was a trade of 259 Common Stock done . Disclosure was reported to the exchange on April 3, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharma | P. Roy Vagelos | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Apr 2023 | 259 | 125,493 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Mar 2023 | 25,000 | 312,578 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 270.43 per share. | 22 Feb 2023 | 42,500 | 366,583 (0%) | 0% | 270.4 | 11,493,275 | Common Stock |
| Regeneron Pharma | P. Roy Vagelos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2023 | 42,500 | 85,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | P. Roy Vagelos | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 750.16 per share. | 22 Feb 2023 | 29,005 | 337,578 (0%) | 0% | 750.2 | 21,758,391 | Common Stock |
| Regeneron Pharma | P. Roy Vagelos | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Feb 2023 | 291 | 125,752 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | 20 Dec 2022 | 111 | 1,961 (0%) | 0% | 729.7 | 80,998 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | 20 Dec 2022 | 30 | 2,072 (0%) | 0% | 728.9 | 21,866 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 16,254 | 16,254 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | P. Roy Vagelos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 1,651 | 324,083 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Dec 2022 | 23,077 | 322,489 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Dec 2022 | 357 | 126,347 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Dec 2022 | 304 | 126,043 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Dec 2022 | 302 | 126,704 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 753.28 per share. | 09 Dec 2022 | 57 | 322,432 (0%) | 0% | 753.3 | 42,937 | Common Stock |
| Regeneron Pharma | P. Roy Vagelos | Director | Sale of securities on an exchange or to another person at price $ 700.00 per share. | 30 Mar 2022 | 14,286 | 23,461 (0%) | 0% | 700 | 10,000,200 | Common Stock |
| Regeneron Pharma | P. Roy Vagelos | Director | Sale of securities on an exchange or to another person at price $ 700.02 per share. | 30 Mar 2022 | 14,286 | 127,006 (0%) | 0% | 700.0 | 10,000,486 | Common Stock |
| Regeneron Pharma | P. Roy Vagelos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 179.13 per share. | 14 Mar 2022 | 75,000 | 393,669 (0%) | 0% | 179.1 | 13,434,750 | Common Stock |
| Regeneron Pharma | P. Roy Vagelos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2022 | 75,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | P. Roy Vagelos | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 655.29 per share. | 14 Mar 2022 | 48,103 | 345,566 (0%) | 0% | 655.3 | 31,521,415 | Common Stock |
| Regeneron Pharma | P. Roy Vagelos | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Mar 2022 | 338 | 141,292 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | 16 Dec 2021 | 107 | 2,095 (0%) | 0% | 635.0 | 67,948 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | 16 Dec 2021 | 19 | 2,202 (0%) | 0% | 634.7 | 12,059 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2021 | 21,198 | 21,198 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | P. Roy Vagelos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2021 | 1,861 | 318,669 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Dec 2021 | 347 | 141,630 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 179.13 per share. | 25 Aug 2021 | 75,000 | 366,090 (0%) | 0% | 179.1 | 13,434,750 | Common Stock |
| Regeneron Pharma | P. Roy Vagelos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2021 | 75,000 | 75,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | P. Roy Vagelos | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 667.39 per share. | 25 Aug 2021 | 49,282 | 316,808 (0%) | 0% | 667.4 | 32,890,314 | Common Stock |
| Regeneron Pharma | P. Roy Vagelos | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Aug 2021 | 22,000 | 327,090 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Aug 2021 | 19,000 | 308,090 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Aug 2021 | 17,000 | 291,090 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | Sale of securities on an exchange or to another person at price $ 650.04 per share. | 18 Aug 2021 | 10,039 | 37,747 (0%) | 0% | 650.0 | 6,525,752 | Common Stock |
| Regeneron Pharma | P. Roy Vagelos | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Aug 2021 | 446 | 142,350 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | P. Roy Vagelos | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Aug 2021 | 373 | 141,977 (0%) | 0% | 0 | Common Stock |